Hematopoietic Stem Cell Transplantation and High Dose Chemotherapy in Recurrent and/or Chemotherapy Resistant Hodgkin Lymphoma Cases: A Single Center Experience
Background: Nearly 20% of patients with Hodgkin Lymphoma (HL) who receive standard treatment will relapse or have a refractory disease. Standard treatment for the Relapsed/Refractory (RR) HL is salvage high dose chemotherapy followed by autologous stem cell transplantation (AuSCT). Management of RR...
Saved in:
| Main Authors: | Yöntem Yaman, Murat Elli, Kürşat Özdilli, Leyla Telhan, Nihan Bayram, Volkan Hazar, Ebru Tuğrul Sarıbeyoğlu, Şifa Şahin, Seniye Sema Anak |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Istanbul University Press
2021-05-01
|
| Series: | Çocuk Dergisi |
| Subjects: | |
| Online Access: | https://cdn.istanbul.edu.tr/file/JTA6CLJ8T5/C8B967475A7D4AC8BC4D423D70C3C8EB |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas
by: EA Demina
Published: (2015-10-01) -
The Use of Brentuximab Vedotin in Relapsed/Refractory Hodgkin’s Lymphoma in the Kransnodar Region
by: OD Serdyuk, et al.
Published: (2018-01-01) -
Co-occurrence of myositis and neuropathy after anti-CD30 therapy in a late-adolescent Hodgkin lymphoma patient
by: Adela Della Marina, et al.
Published: (2025-06-01) -
Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01) -
Hodgkin Lymphoma Treatment With Brentuximab Vedotin in a Patient With HIV, Liver Failure, and Anemia Without Transfusion
by: Ellen Marin, et al.
Published: (2025-02-01)